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ABSTRACT 
 
Cancer is a complex disease. It is a multistep process where genetic changes lead 
to cellular transformation and uncontrolled proliferation. However, cancer is 
not only a disease of these transformed cells, since tumor stroma and 
microenvironment synchronously evolve and become activated together with 
these genetic changes. The interactions between different cell types in tumor 
microenvironment are mediated by soluble factors, such as cytokines, 
chemokines, growth factors and proteases. They modulate cell proliferation, 
activation and differentiation, as well as the composition of the extracellular 
matrix in tumor and its microenvironment.  
Nemosis is an in vitro model of fibroblast activation, which is initiated by 
forcing fibroblast to cluster together instead of providing solid support for 
attachment. This results in a multicellular spheroid that upregulates soluble 
paracrine molecules known to be important mediators of tumor 
microenvironment. Furthermore, nemotic fibroblasts affect cancer cell 
proliferation, invasion and differentiation through these soluble factors. In 
addition to direct effects on cancer cells they stimulate angiogenesis and the 
chemotaxis of leukocytes.  
This thesis study shows that fibroblast spheroid formation depends on the 
interaction between fibronectin (FN) with its integrin receptors, more accurately 
!5 and #1 integrin subunits, whereas fibroblasts activation in spheroids was 
mediated by the interaction of FN with !5, !V and #1 integrin subunits. The 
activation was mediated by the binding of integrins to the RGD -motif in FN 
molecules and the synergy site that is known to stimulate RGD-motif binding to 
integrins enhanced it. Unexpectedly, FN-matrix assembly was not essential for 
the activation of fibroblasts in spheroids although it had an effect on spheroid 
formation. FN deposit to matrix is an acknowledged consequence of integrin 
binding to fibronectin.  
Nemosis was accompanied by a dramatic change in gene expression. The 
change could be roughly categorized in three classes; the upregulation of 
secreted molecules and downregulation of cell cycle and cytoskeleton. Nemosis 
was associated with a quiescent withdrawal from the cell cycle, as the cells 
downregulated cyclin D and upregulated p27, the driver and the inhibitor of the 
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cell cycle, respectively. Furthermore, nemotic fibroblasts resumed to the cell 
cycle when taken out from the spheroid, indicating reversible cell cycle arrest, a 
known characteristic of quiescence.  
Fibroblast activation by spheroid formation was accompanied by stress-
related changes in the cellular ultrastructure, such as dilated endoplasmic 
reticulum, increased lipofuscin and degenerated organelles. Hence, nemosis is a 
cellular stress response. This observation was in agreement with the induction 
of autophagy in fibroblasts spheroids. Autophagy is a well-known stress 
response that helps cell survival under stress conditions. Furthermore, nemosis 
resembled another cellular stress condition, the cellular senescence. They both 
had a similar secretory phenotype, expressed senescence-associated #-
galactosidase and lipofuscin, and there was a cell cycle arrest in both. However, 
there were also features to distinguish nemosis from senescence, such as 
nemosis being a reversible phenotype, and cell cycle inhibitors that regulate 
senescence being downregulated in nemosis.  
Nemosis attenuated tumor growth in vivo in a mouse xenograft model. The 
attenuation was associated with the expression of senescence-associated #-
galactosidase and the expression of the p14ARF cell-cycle inhibitor in human 
RT3 malignant keratinocytes. This suggests that nemosis causes cellular 
senescence in the RT3 keratinocytes in vivo. In addition to the senescence 
response, nemosis was found to increase the cytokeratin-7 (CK7) mediated 
differentiation of RT3 cells in xenografts.  
It is becoming obvious that cancer is not just a disease of uncontrolled 
proliferation of cancer cells, but a disease where normal stromal fibroblasts 
actively participate in its progression. The current work reveals new mechanistic 
insights of fibroblast activation and concludes that nemosis can be a useful 
model to study the activation of fibroblasts and interactions between fibroblasts 
and cancer cells. 
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1. REVIEW OF LITERATURE 
 
1.1 Cancer 
 
Cancer is a leading cause of death and accounted for 7.6 million deaths 
worldwide in 2008, according to World Health Organizations GLOBOCAN 
2008 –project [1]. Cancer is more a term for a vast group of different diseases 
than just one specific disease. It is a disease where malignant cells proliferate 
and grow uncontrollably. Cancers are classified according to their cellular 
origin. Cancers originating from epithelial tissues, carcinomas, are responsible 
for ~80% of cancer-related deaths in the western world. Non-epithelial cancers 
can be classified in three different classes according their embryonic origin. 
Sarcomas are derived from mesenchymal cells, like fibroblasts, adipocytes, 
osteoblasts and myocytes. The second group of non-epithelial cancers originate 
from hematopoietic (blood-forming) cells. Leukemias and lymphomas are two 
major subtypes of these cancers. The last major group of non-epithelial cancers 
is derived from various components of the central and peripheral nervous 
system. These cancers (gliomas, glioblastomas, neuroblastomas, schwannomas 
and medulloblastomas) are rare, but very deadly. Some cancers, such as 
melanoma that originates from melanocytes, cannot be grouped in any of the 
above-mentioned major classifications [2]. 
Cancer progression is a multistage process, where a normal cell transforms 
from a pre-cancerous lesion to a malignant tumor. These changes are driven by 
mutations in the cellular genome, which are the result of interaction of genetic 
and environmental factors. Hanahan and Weinberg stated six hallmarks of 
cancer (sustaining proliferative signaling, evading growth suppression, 
activation of invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis, resisting cell death), two emerging hallmarks (deregulated cellular 
energetics, avoiding immune destruction) and two enabling characteristics 
(genome instability and mutation, tumor-promoting inflammation) (Table 1) 
[3]. The cells acquire these capabilities during a multistep process that is 
required for the progression from a benign to malignant cell and the formation 
of a tumor. In addition to these malignant cells, tumors consist also of a variety 
of untransformed stromal cells, such as fibroblasts, pericytes, and endothelial 

 - Review of literature - 
13 
 
In addition to maintaining proper 
ECM structure, fibroblasts can serve as 
sentinel cells. They initiate and modulate 
inflammatory processes by secreting 
various cytokines and chemokines, as well 
as releasing growth factors from the ECM 
by secreting proteases [9-12]. In normal 
healthy tissue, fibroblasts maintain in a 
less active state, but in pathological 
conditions, such as inflammation, wound healing or cancer, fibroblasts become 
activated [5]. Activated fibroblasts express !-smooth muscle actin (!-SMA) and 
the extra domain A (EDA) containing splice variant of FN, which are used as 
markers of activated fibroblasts, or so-called myofibroblasts [13]. Interestingly, 
the activated fibroblasts can make direct cell-cell contacts through gap junctions 
and form a body-wide network [14-16]. 
 
1.2.1 Fibroblasts in tumor microenvironment 
 
Activated fibroblasts in tumors are often called cancer-associated fibroblasts 
(CAFs). They are the most abundant stromal cell type in cancer and in some 
cancers stromal cells can even create most of the tumor mass [17]. CAFs are a 
highly heterogeneous population and they, like myofibroblasts, have different 
cellular origins. The main progenitor of CAFs are local resident fibroblasts, but 
they can also originate from smooth-muscle cells, pericytes and bone marrow-
derived mesenchymal stem cells, or as a result of epithelial-mesenchymal 
transition (EMT) or endothelial-mesenchymal transition (EnMT) [18-21]. 
Activated fibroblasts share many consistent features regardless of their origin 
and tissue type. To describe this analogy between stroma in cancer 
microenvironment and wound healing, Dvorak used the famous quotation of 
tumors: “wounds that do not heal” [22].  
The exact mechanism of how resident fibroblasts become activated to CAFs 
is under intense investigation. Several hypotheses have been postulated; acute 
phase and stress response, fibroblasts senescence, interaction with cancer cells 
and somatic mutations in fibroblasts [23]. Maffini et al. showed that cancer 
Figure 1. Phase-contrast image of ECM 
produced by confluent fibroblasts 
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progression in response to the carcinogen N-nitrosomethylurea depends on 
stress-related changes in stromal cells and not on the direct effects of 
carcinogens on epithelial cells [24]. Age correlates with chronic increase in 
tissue inflammation [25, 26], as well as cancer incidence [27]. In addition to 
these assumptions, senescent fibroblasts secrete various inflammatory cytokines 
to maintain an inflammatory state [28]. In addition, senescent fibroblasts have 
gene expression profiles similar to CAFs, which has led to the hypothesis that 
they might be a source of CAFs [23]. Several experiments have shown that the 
co-culture of fibroblasts with cancer cells leads to the myofibroblast 
differentiation of fibroblasts and growth promotion of cancer cells [29-32]. 
Mutations in tumor suppressor genes, such as PTEN and p53, in stromal 
fibroblasts also activate fibroblasts and promote tumor growth [33-35].  
CAFs have both direct and indirect effects on cancer cells. Hence, the variety 
of growth factors and cytokines they produce exert their paracrine effects 
directly on cancer cells as well as other cell types in the tumor, which further 
stimulates or inhibits tumor progression [12]. They also produce proteases, such 
as matrix metalloproteinases (MMPs) and plasminogen activators that 
modulate the ECM structure, as well as release and activate growth factors 
embedded in it [36-38]. 
It is well appreciated that CAFs support and promote tumor growth. In 
addition, several studies have shown that CAFs can even cause epithelial cell 
transformation and initiate tumor growth [39]. In contrast to CAFs, normal 
fibroblasts can convert malignant epithelia to benign lesions [12, 39]. It remains 
unclear how normal fibroblasts limit cancer progression, but it has been 
suggested that fibroblasts as a source of immuno-modulatory cytokines, such as 
IL-6, provoke immune defense against cancer cells [12]. In addition, Mina 
Bissell’s laboratory has found that ECM structure affects cancer cells’ malignant 
phenotype and vice versa, proper ECM can convert malignant cells to benign, 
and thus limit cancer progression [40-42].  
 
1.2.2 Cells in tumor microenvironment 
 
In addition to cancer cells and fibroblasts, tumors contain other cell types, 
which all can affect tumor growth. Hence, tumors must be seen as complex 
organs where the complicated interplay of various cells affects the outcome. 
 - Review of literature - 
15 
Cancer cells themselves are considered to be a heterogeneous population and 
according to one theory all cancer cells in tumors originate from cancer stem 
cells (CSCs). CSCs are tumorigenic cells that express markers of stem cells and 
have the ability of self-renewal [43]. Although CSCs cause cellular heterogeneity 
within tumors, most heterogeneity is generated by the stromal compartment. 
Interactions between tumor-stromal cells have a fundamental role in tumor 
initiation and progression. This interaction leads to co-evolution of cancer cells 
and their microenvironment. It has been postulated that co-evolution can 
develop in two ways: transformed epithelia causes activation and changes in 
microenvironment, or stromal changes occur first leading to subsequent 
transformation of epithelial cells [44].  
Tumor growth, as well as normal organ growth, depends on the formation of 
novel blood and lymphatic vessels, angiogenesis and lymphangiogenesis, 
respectively. Blood vessels are assembled from endothelial cells that form the 
interlining of the vessels, and pericytes and smooth muscle cells, which give 
structural support for the vessels. Endothelial cells in already-formed vessels 
retain their ability to become activated and divide in response to angiogenic 
factors, such as VEGF and FGF, released by cancer cells to initiate angiogenesis 
[45].  
Tumor microenvironment is very inflammatory (wound that never heals), 
hence it is not surprising that the cells of the immune system have a complex 
impact on tumor growth [46]. Leukocytes can have either antagonistic or 
tumor-promoting effects. It is clear that cancer cells must avoid immune 
destruction to fully develop, as stated by Hanahan and Weinberg as an emerging 
hallmark [3]. This immune destruction, also known as immunosurveillance, is 
mainly mediated by cytotoxic T cells and natural killer cells [47], whereas 
macrophages, mast cells, neutrophils, and B and T lymphocytes promote tumor 
growth by secreting growth factors, cytokines, chemokines and proteases to 
increase angiogenesis, cancer cell proliferation and invasion [46, 48]. Moreover, 
they further amplify the inflammatory state of tumors, which causes an increase 
in the production of reactive oxygen species (ROS) that leads to additional 
genomic instability in cancer cells [46].  
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1.2.3 Fibronectin 
 
FN is a ubiquitous glycoprotein that is found in ECM and body fluids. FN 
protein is secreted from cells as a dimer and assembled to a multimeric matrix 
in an integrin-mediated process. Two types of FN are found, soluble plasma FN 
(pFN) and insoluble cellular FN (cFN). Hepatocytes synthesize pFN and it is a 
major component of the plasma (300 µg/ml). Several cell types are able to 
produce cFN, but it is primarily produced by fibroblasts [49-52]. It is 
synthesized as a soluble form and is then assembled into ECM [53]. FN is a 
product of a single gene and it contains three types of repeating units (type I, II 
and III), but in humans alternative splicing can generate 20 different isoforms. 
Splicing can occur in three different splice sites celled EDA, EDB and V 
(variable) (Figure 2.). EDA and EDB can be either completely excluded or 
included and are present in cFN and very rarely in pFN. V domain can be 
alternatively spliced in five different regions [51].  
 
Figure 2. The structure of fibronectin 
 
FN mediates cell adhesion to ECM and plays an important role in cell 
migration, differentiation and growth. FN deposition to ECM is a complex, 
tightly regulated, cell mediated process, which is initiated by soluble FN binding 
to integrins. This causes FN-bound integrins to cluster, bringing FN molecules 
in close proximity to interact with one another [54]. It is not completely known 
how final insoluble matrix is formed, but it seems that dimeric FN is stretched 
to uncover cryptic bindings sites along the FN molecule [53] and interaction 
with fibrillin is needed to make large insoluble matrix [55].  
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1.3 Autophagy 
 
Autophagy is an evolutionarily conserved pathway that exerts protein and 
organelle degradation. It has an essential role in development, cell survival, 
homeostasis and immune response. Autophagy is a “self-eating” process where 
cytosolic cargo is delivered to lysosomes for catabolic and energy-generating 
degradation of the engulfed material. In addition to the energy-generating role 
of autophagy, constitutive autophagy has a housekeeping role in the clearance of 
damaged organelles and misfolded or aggregated proteins to maintain cellular 
homeostasis [65]. Furthermore, various cellular stress conditions, such as 
starvation, hypoxia, unfolded protein response and infection, induce autophagic 
activity [66]. 
 
 
 Figure 3. The main events in macroautophagy. In response to stress cytosolic 
material is sequestered to autophagosome. Autophagosomes fuse with 
lysosomes for degradation of the cargo [65]. 
 
The delivery of material to lysosomes can occur in three different ways, 
macroautophagy, microautophagy or chaperone-mediated autophagy (CMA). 
They differ from each other by the way they target cytosolic cargo to lysosomes. 
In macroautophagy, hereafter called autophagy (as in most literature), cytosolic 
material is first sequestered by double-membrane structures, phagophores, 
which are then sealed to form double-membrane vesicles, autophagosomes. 
Autophagosomes fuse with lysosomes to form autolysosomes for degradation of 
the cargo carried by autophagosomes (Figure 3) [65]. In microautophagy, 
endosomes and lysosomes sequester cytosolic material directly without initial 
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well as nutrient, growth factor and stress levels [77]. When nutrient levels are 
high and cells are in a stress-free environment, mTOR remains activated and 
inhibits autophagy by phosphorylating the unc-51-like kinase (ULK) 1 or 2 
(mammalian homologs for Atg1), which form a complex with Atg13 and FIP200 
[78]. When the activity of mTOR is inhibited, ULK1/2 is dephosphorylated 
together with Atg13, and becomes able to phosphorylate FIP200, which triggers 
initial autophagosome formation (Figure 4) [78]. Recently it was shown that 
AMPK can directly activate ULK1 through phosphorylation, in addition to its 
ability to inhibit the activity of mTOR [79]. 
 
 
Figure 4. The overview of mTOR pathway that regulate autophagy. 
AMPK = AMP-activated protein kinase. For other abbreviations see 
text. 
 
Beclin-1 together with class III PI3K, also called Vps34, drives the 
nucleation of autophagosomes. The binding of Vps34 with Beclin-1 promotes its 
catalytic activity to generate phosphatidyl inositol 3-phosphate, a phospholipid 
that is required for autophagosome formation [80]. The most widely used 
autophagic inhibitor, 3-methyladenine (3-MeA), targets class III PI3K and thus 
blocks the early steps of autophagosome formation [81].  
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There are two important ubiquitin-like conjugation systems that are 
required for the autophagic process, Atg12-Atg5 and microtubule-associated 
protein light chain (LC3, Atg8)-phosphatidyl ethanolamine (PE). Atg12-Atg5 
conjugate is a ubiquitin ligase E3-like enzyme that assists the formation and 
elongation of the autophagosome, but dissociates when the autophagosome is 
complete, whereas conjugated LC3 stays in the autophagosome [82]. Upon the 
induction of autophagy, LC3 is cleaved by Atg4 to generate LC3-I. LC3-I is then 
conjugated to PE to form LC3-II, which localizes to inner and outer membranes 
of the developing autophagosome. This step is required for proper 
autophagosome formation [83]. In addition to aiding autophagosome 
formation, LC3 interacts with most of the known receptors and substrates of 
selective autophagy [69]. The receptors for selective autophagy, such as 
sequestosome 1 (p62/SQSTM1), interact with cargo and LC3, often through 
ubiquitin, to target cargo to the forming autophagosome (Figure 5) [84-86].  
 
 
Figure 5. Molecular and cellular events during autophagy. ULK1 together with FIP200 and 
Atg13 regulates initial autophagosome formation. Beclin-1 binds Vsp34 and drives nucleation of 
forming autophagosomes. The mature autophagosome fuses with a lysosome to degrade 
autophagosomal cargo with lysosomal hydrolases. LC3 is required for autophagosome 
formation. In addition LC3 can bind p62 that binds to polyubiquitinated protein aggregates and 
organelles to target them into forming autophagosome. shATG5 and 3-MeA prevent initial 
formation of autophagosome, whereas Baf A1 inhibits fusion of autophagosome and lysosome.  
 
After the autophagosome is formed it matures and then fuses with a 
lysosome to degrade its content using lysosomal hydrolases. Although this 
pathway is not fully understood, it is known to converge with the endocytic 
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pathway. It has been suggested that the autophagosomes fuse with early and late 
endosomes prior to fusion with lysosomes [87]. It has also been postulated that 
the maturation requires multivesicular bodies (MVBs), which provide a 
platform for sorting events in the endocytic pathway [88, 89]. The fusion events 
are mediated by the endocytic factors, such as Rab7 that associates with the 
autophagosomes and mediates the fusion of the outer membrane of the 
autophagosome with the lysosomal membrane in a LAMP1/LAMP2 –dependent 
manner to form an autolysosome [90, 91]. The detailed mechanism that 
mediates the autophagosome maturation and fusion with lysosomes is still 
partly uncharacterized, but recently it was shown that SNARE proteins that 
mediate vesicle fusion are required for the proper maturation of 
autophagosomes and their fusion with lysosomes [92, 93]. In addition, it has 
been suggested that also ESCRT proteins, which have been initially 
characterized to regulate the biogenesis of MVBs, plays an important role in the 
autophagosome-lysosome fusion, since impairing their function leads to the 
accumulation of autophagosomes [94, 95].  
The final stage, the degradation of autolysosomal content, contains two 
steps; first a putative lipase Aut5p/Atg15p degrades the inner membrane of the 
autophagosome and after that the lysosomal content (acid hydrolases) is 
released to the autophagosome to degrade its cargo [96]. The degradation 
products, such as amino acids and monosaccharides, are transported out of the 
autolysosomes through the lysosomal membrane and recycled [97].  
 
1.3.3 Autophagy in cancer 
 
The role of autophagy in cancer is complex: it can be both a tumor-suppressive 
and tumor-promoting, depending on the type and stage of the tumor. Basal 
autophagy is considered to be tumor suppressive by clearing the damaged 
organelles and protein aggregates that are toxic to cells and cause genomic 
instability. This is supported by the finding that Beclin 1 gene is monoallelically 
deleted in 70% of ovarian, 50% of breast and 40% of prostate cancers [98]. 
Furthermore, overexpression of Beclin 1 in breast cancer cells leads to decreased 
tumorigenicity and has been related to increased autophagy [99]. Mathew et al. 
showed that defective autophagy caused p62 accumulation, which led to 
increased tumorigenesis through deregulated nuclear factor-"B (NF-"B) 
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signaling, elevated ROS production and DNA damage [100]. p62 is a signal 
modulator and adaptor protein that functions as a scaffold for several signaling 
proteins such as RIP, TRAF6, ERK, aPKC and caspase-8 (Figure 6) [101]. In 
addition to these interaction partners, p62 uses its PB1 domain for self-
oligomerization to generate intracellular speckles or aggregates to form signal-
organization centers [101, 102]. The levels of p62 are controlled by autophagy 
through LC3-interaction region (LIR) that binds to LC3 and targets p62 for 
degradation in autophagosomes [103]. Furthermore, through its ubiquitin-
associated (UBA) domain p62 binds polyubiquitinated proteins and organelles, 
such as misfolded and aggregated proteins, and dysfunctional organelles, for 
their clearance through autophagy. By removing these dangerous cytosolic 
elements, p62 protects cells from oxidative and genotoxic stress. Hence, p62 is a 
tumor suppressor that functions as a receptor for selective autophagy [104].  
 
 
Figure 6. The structural domain organization of p62 and its interaction partners [101, 
102]. 
 
In addition to autophagy’s ability to prevent genotoxic stress, the induction 
of autophagy is required for mitotic transition to oncogene-induced senescence 
[105], an irreversible cell-cycle arrest that provides resistance against cellular 
transformation [106]. p53, a regulator of senescence, apoptosis and cell-cycle 
arrest, that is most commonly mutated in cancers [107], induces autophagy to 
protect cells from malignant transformation [108-110].  
The role of autophagy in cell death is complex. Although in most cases the 
basal autophagy supports cell survival by removing damaged proteins and 
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organelles, prolonged and/or high levels of autophagy can lead to subsequent 
autophagic cell death, also known as type II programmed or cytosolic cell death 
[111], which further corroborates the role of autophagy in tumor suppression. 
The suppression of apoptosis induces autophagy, whereas the inhibition of 
autophagy upregulates apoptosis [112, 113]. Although the link between apoptosis 
and autophagy is not so straightforward, both are regulated by a set of common 
molecules and can occur in the same cell [113]. Furthermore the increased 
autophagy can lead to a subsequent apoptosis response [114, 115]. In addition to 
increased apoptosis, autophagy can lead to catalase depletion dependent (ROS 
mediated) necrosis in cells where caspase activity is inhibited [116]. In contrast, 
in the cells where apoptosis is impaired, such as in cancer cells, the inhibition of 
autophagy increases the necrotic form of cell death [117, 118], highlighting the 
role of autophagy in the resistance against both apoptosis and necrosis.  
During tumor progression, the role of autophagy changes from tumor 
suppressive to tumor promoting. It is well-established that autophagy promotes 
cell survival under various stress conditions, like hypoxia and starvation. When 
the size of the tumor exceeds a certain limit, some areas become deprived of 
oxygen and/or nutrients, which leads to increased necrosis [119]. In these areas 
autophagy promotes tumor growth by improving cell survival during hypoxic 
stress as well as by providing amino acids and carbohydrates for energy source 
[120]. In opposition to this theory, Degenhardt et al. showed that in the 
apoptosis-defective cells, autophagy restricted tumorigenesis, although it 
promoted cell survival by preventing necrosis in the tumor. This restriction was 
provoked by reduced necrosis-mediated infiltration of the tumor growth 
supporting inflammatory cells and the inflammatory state of the tumor [117]. In 
addition to increased survival during hypoxia and starvation, autophagy can 
promote the therapeutic resistance of the tumor [121]. Many chemotherapeutic 
treatments, such as toxic compounds, induce autophagy that in turn increases 
survival and counteracts cell killing. The combination of simultaneous 
chemotherapy and autophagy inhibition has been shown to potentiate cell 
killing in several studies [122].  
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1.3.3.1 Autophagy in tumor stroma and fibroblast activation 
 
Michael Lisanti’s group has extensively characterized a model for CAF activation 
called “The Autophagic Tumor Stroma Model of Cancer Cell Metabolism” [123, 
124]. In this model cancer cells increase ROS production through 
downregulation of the scaffolding protein caveolin-1 (Cav-1) [125-127]. In 
addition to being a structural component of caveolae, Cav-1 inhibits a variety of 
signaling pathways, such as mitogen-activated protein kinases and PI3K [128, 
129], whereas it is required for FN-integrin mediated signaling [130, 131]. The 
loss of stromal Cav-1 is a powerful independent biomarker for early tumor 
recurrence, metastasis and poor prognosis [132, 133].  
The loss of Cav-1 expression in fibroblasts leads to myofibroblastic (!-SMA 
and vimentin expression) differentation [134]. Cav-1 degradation was found to 
depend on autophagy and moreover, Cav-1 downregulation in fibroblasts caused 
induction autophagic activity [135]. Cav-1 downregulation and myofibroblast 
differentiation was driven by the conditions that upregulate ROS production in 
mitochondria, such as the dysfunction of mitochondria and hypoxia [136, 137]. 
In addition to induced myofibroblast markers, oxidative stress was shown to 
drive the activation of the transcription factors hypoxia-inducible factor-1! 
(HIF-1!) and NF-"B [136], which increased the secretion of inflammatory 
mediators, such as interleukin-6 (IL-6), IL-8, IL-10, macrophage inflammatory 
protein-1! (MIP-1!), interferon-%, RANTES (CCL5) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [138].  
These activated fibroblasts also shift their metabolic regulation to aerobic 
glycolysis (The so called Warburg effect) [139]. In the Warburg effect, cancer 
cells produce energy using unusually high rate of glycolysis and lactate 
production in cytosol even in the presence of oxygen instead of oxidation of 
pyruvate in mitochondria like normal cells [140, 141]. Hence, Pavlides et al. 
called this stromal glycolysis as “Reversed Warburg effect” [139]. When 
fibroblasts use glycolysis to produce energy they secrete high-energy 
metabolites, such as lactate, ketone and pyruvate to the microenvironment 
[142]. These energy metabolites together with the secreted inflammatory 
mediators were shown to enhance the proliferation of the neighboring cancer 
cells [143]. Induction of Pyruvate kinase (PK) isozyme M2 drives Warburg effect 
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in cancer cells [144]. To further elaborate the role of Warburg effect in the 
stromal fibroblasts, Chiavarina et al. overexpressed PK isozymes M1 and M2 
and activated aerobic glycolysis pathway (Reversed Warburg effect) for ATP 
generation in fibroblasts. These M1-PK or M2-PK overexpressing fibroblasts 
promoted tumorigenesis through different mechanisms. The M1-PK 
overexpression increased tumor inflammation and produced lactate for an 
energy source to cancer cells, whereas M2-PK overexpression led to “pseudo-
starvation” response with increased autophagy in fibroblasts and increased 
ketone-body production as a energy source to cancer cells [145]. Furthermore, 
upregulation of these enzymes was found in Cav-1 negative fibroblasts in human 
breast cancer samples [145].  
 
1.4 The Cell cycle 
 
Active cell cycle results in the proliferation of cells. The cell cycle consists of four 
different phases: Gap 1 (G1), Synthesis (S), G2, and Mitosis (M). During G1 cell 
size increases and the decision whether the cells will move on to the phase S is 
made according to external signals, such as the presence of mitogens and 
nutrients. When DNA is duplicated in the S phase, the cells move on to G2 to 
further grow in size to prepare for cell division in mitosis (M phase). In the M-
phase the cell growth and protein production are stopped as cells use their 
energy for division into two daughter cells [146].  
The progression through the cell cycle phases is controlled accurately and 
specifically by cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent 
kinase inhibitors (CDIs) (Figure 5) [147]. Varying the concentrations of cyclin 
proteins through different cell-cycle phases drives the progression of the cell 
cycle [148, 149]. Cyclins form a complex with CDKs and activate them through 
phosphorylation [147]. The levels of D-type cyclins, controlled by the 
extracellular environment, start to increase in early G1 and they form complexes 
with CDK4 and CDK6 [150]. Cyclin E starts to accumulate close to G1/S 
transition and activates specially CDK2. Both cyclin D-CDK4/6 and cyclin 
E/CDK2 -complexes hyperphosphorylate retinoblastoma (RB) protein to release 
E2F transcription factor bound to it [151]. The released E2F can subsequently 
push cells to the S phase by regulating the expression of genes necessary for the 
S phase entry [152]. In the S phase, also cyclin A can activate CDK2 and control 
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the progression towards G2 when the levels of cyclin E start to decrease. During 
the G2/M transition cyclin A-CDK1 activity is needed. Finally, cyclin B-CDK1 
complex mediates the progression and the completion of mitosis (Figure 7) 
[153].  
 
Figure 7. Cyclins and cyclin dependent kinases in different cell cycle 
phases [147]. CDK, cyclin-dependent kinase. CDI, cyclin-dependent 
kinase inhibitor. 
 
1.4.1 Checkpoints 
 
The progression of cell cycle and activities of cyclin-CDKs are controlled by 
checkpoints under normal, as well as stress conditions, such as DNA damage, 
and telomere dysfunction. If the preceding phase of the cell cycle is not finished 
or the cell has reparable or irreparable damage, the cell cycle is arrested to the 
checkpoint by CDIs [154, 155]. There are two families of CDIs: the INK4 family 
(p15, p14Arf, p16, p18) binds to CDK4 and CDK6 to prevent cyclin D activity and 
the Cip/Kip family (p21, p27, p57) binds and inhibits cyclin E-CDK2, cyclin A-
CDK2, cyclin A-CDK1 and cyclin B-CDK1 (Figure 7) [146].  
There are multiple checkpoints in different stages along the cell cycle. The 
best-known checkpoint, the DNA damage checkpoint, is always active even in 
the non-cycling cells, such as in differentiated and quiescent cells. If DNA 
damage is reparable, the cells return to the cell cycle after the damaged DNA is 
repaired. Whereas if DNA damage is irreparable, the cells withdraw 
permanently from the cell cycle by the induction of cellular senescence, or die 
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through apoptosis. The DNA-damage checkpoints occur at the G1/S and G2/M 
boundaries, but can occur also in the middle of the S phase. DNA damage is 
detected by using sensor mechanisms and the checkpoints are activated by two 
master kinases, ATM and ATR [156].  
The G1 checkpoint, also known as a restriction point, is located at the end of 
G1 just before the entry into the S phase. At this point the cells make the 
decision whether they should divide, delay division or withdraw from the cell 
cycle to the resting stage G0, also called quiescence. When the cell progresses 
through this restriction point, the completion of the cycle becomes independent 
of growth factors [157].  
 
1.4.3 Quiescence 
 
Cellular quiescence (G0) is a common state of somatic cells where proliferation 
is reversibly arrested due to environmental reasons. When the cells proceed to 
the quiescence they exit from the cell cycle in G1 [158]. This is induced by 
contact inhibition, the loss of anchorage or nutrient and/or growth factor 
deprivation [159]. The transition to G0 is mediated by the downregulation of the 
cell cycle-related genes, rather than the induction of the cell cycle inhibitors 
[160], although CDI p27 plays an important role in the initiation and 
maintenance of the quiescent state. Quiescent fibroblasts are not only passively 
arrested from the cell cycle, but they seem to posses a controlled program where 
reversibility is insured, and they maintain high metabolic activity [161]. 
Furthermore, terminal differentiation, apoptosis and senescence states are 
actively suppressed [159].  
 
1.4.4 Cellular senescence  
 
Cellular senescence is a tumor suppression mechanism, where cells are 
terminally withdrawn from the cell cycle [162] in response to a variety of 
intracellular or extracellular stressors such as telomere erosion (replicative 
senescence), oxidative stress, irreparable DNA damage and oncogenic 
stimulation (oncogene-induced senescence; OIS) (Figure 8) [163]. Senescence is 
characterized by enlarged flattened cell morphology, the lack of DNA replication 
and positivity for senescence-associated #-galactosidase (SA-#$gal) [163, 164]. 
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The irreversible growth arrest in senescence is controlled by the activity of 
major tumor-suppressor pathways: p21, p53, retinoblastoma (RB) and p16 
[163]. The induction of these proteins has been used as a marker of senescent 
cells both in cell culture and in vivo.  
 
 
 Figure 8. Cellular senescence is induced by a variety of DNA damage causing stressors. 
SA-#-gal, Senescence-associated-#-galactosidase. 
 
Cellular senescence was first discovered by Leonard Hayflick in 1961, when 
he observed that fibroblast cells can divide 40 to 60 times [165]. This was called 
Hayflick’s limit [166] and was found to be due to the erosion of telomeres during 
the cell division [167]. This led to the hypothesis that organism aging is 
dependent on cellular senescence, which was strengthened by the observation 
that during the aging senescent cells accumulate in to the tissues [164, 168, 169]. 
Furthermore, it was discovered recently that the clearance of the senescent cells 
from the tissues delays ageing-associated disorders [170].  
It has been suggested that the senescent cells secrete components that 
mediate tissue degenerative effects [171]. In addition to the ageing-associated 
disorders these components also have a great impact in cancer and 
inflammatory conditions. Coppe et al. found that upon induction of senescence, 
the cells acquire a senescence-associated secretory phenotype (SASP), where 
they secrete various inflammation- and malignancy-associated growth factors 
 - Review of literature - 
30 
such as hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), 
vascular endothelial growth factor (VEGF), cytokines and chemokines including 
IL-1, IL-6, GM-CSF, granulocyte colony-stimulating factor (G-CSF), IL-8, 
monocyte chemotactic protein-1 (MCP-1), growth-related oncogene ! (GRO!) 
and matrix metalloproteinases (MMP-1, MMP-10, MMP-14) [172]. These 
secreted factors may even drive the transformation of the adjacent benign 
epithelial cells and stimulate the growth and invasion of cancer cells [172]. SASP 
has also effects on other non-transformed cells, as evidenced by the increased 
infiltration of leukocytes, the stimulation of angiogenesis and the differentiation 
of various cell types. Interestingly, some of the secreted SASP factors can also 
potentially induce or reinforce senescence in normal cells and are part of the so-
called “senescence-messaging secretome” (SMS) [173]. Several of these SMS 
factors activate transcription factor CCAAT/enhancer-binding protein # 
(C/EBP#) in target cells, which in turn is able to enhance senescence response 
and further increase the secretion of SMS factors [28, 174]. Although senescence 
is considered to be the first line of defense against oncogenic transformation, it 
seems to have intricate effects on the nearby cells. 
 
1.5 Nemosis 
 
Nemosis is a novel fibroblast activation model [175]. In vitro, nemosis is 
initiated by plating fibroblasts on a non-adhesive substratum causing them to 
spontaneously adhere together, forming multicellular spheroids [176]. This 
process of activation was named after Nemesis, Greek goddess of retribution 
and inevitable consequence [177]. The formation of fibroblast spheroid is 
associated with increase in expression of inflammatory and tumor associated 
cytokines and growth factors [177-182] as well as fibroblast activation protein 
(FAP) [178], a marker of activated fibroblasts [12]. Hence, nemotic fibroblast 
express similar genes that activated fibroblast express in wound and tumor 
microenvironments [5, 12]. 
The initial hallmark of nemosis was considered to be the induction and 
activity of the stress-related enzyme cyclo-oxygenase-2 (COX-2). Moreover, the 
modulation of COX-2 activity with non-steroidal anti-inflammatory drugs 
(NSAIDs) was found to inhibit its induction in nemosis, whereas addition of its 
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Nemotic fibroblasts are able to attract neutrophils and monocytic THP-1 
cells in vitro. Neutrophil chemotaxis is mostly dependent on IL-8 secreted by 
fibroblast spheroids, whereas THP-1 chemotaxis is mediated by the activation of 
receptors for MIP-1! and RANTES [179]. In addition to chemotaxis, nemosis 
also stimulates THP-1 adhesion to endothelium and the opening of endothelial 
tight junctions, thus activating the extravasation of monocytes from the 
circulating blood to the tissue [185]. Furthermore, fibroblast spheroids cause 
cell cycle arrest and differentiation of monocytic THP-1 and KG-1 cells to 
dendritic or macrophage-like cells, which suggests their activation [181].  
In addition to activation, as mentioned above, nemosis induces an 
angiogenic response in endothelium. In cell culture model, nemotic fibroblasts 
increased migration, motility and cell sprouting of HUVEC cells by secreting the 
angiogenic growth factors HGF and VEGF [182].  
 
1.5.2 Nemosis and cancer 
 
Nemosis has effects on different cell types that are important in the 
microenvironment of wounds and tumors. In addition to controlling the 
development of microenvironment, nemosis also has a direct impact on cancer 
cells. Many in vitro experiments have indicated that nemotic fibroblasts induce 
more migratory, invasive and proliferative phenotypes of cancer cells [177, 181, 
186]. The above-mentioned effect on monocytic leukemia cell differentiation 
and cell cycle arrest were only applicable for c-Met (receptor for HGF) negative 
leukemia cells and where counteracted by the introduction of c-MET expression 
[181]. The cell cycle arrest and differentiation effect were suggested to result in 
response to molecules (IL-1#, IL-6, IL-8, IL-11, GM-CSF and LIF) secreted by 
nemotic fibroblasts, whereas active HGF/c-Met pathway was somehow able to 
counteract their effects. The differentiation of KG-1 and THP-1 cells was 
accompanied by increased expression of the cell surface markers CD45RA, 
CD11c, CD86, CD54 and CD13, indicating phenotype change to antigen-
presenting cells. The differentiation was also associated with increased 
chemotaxis towards the nemotic fibroblasts [181]. 
Conditioned medium from nemotic fibroblasts stimulates HGF-dependent 
outgrowth and invasiveness of c-Met positive melanoma cells [177], as well as 
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motility and proliferation of keratinocytes, presenting different stages of skin 
carcinoma progression. Nemosis stimulates benign and low-grade malignant 
keratinocyte invasion, whereas it was unable to further stimulate the 
invasiveness of metastasizing keratinocytes [186]. Moreover, the two-directional 
interaction between cancer cells and nemotic fibroblasts is highlighted by the 
findings showing that conditioned medium from melanoma cells, or co-culture 
with squamous carcinoma cells causes fibroblasts to spontaneously form 
spheroid-like structures in adherent cultures [177, 178]. 
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2. AIMS OF THE STUDY 
 
Nemosis is a novel type of fibroblast activation that is initiated by fibroblast 
spheroid formation. Nemosis can regulate the differentiation of leukemia cells, 
invasion of melanoma cells, proliferation and migration of malignant 
keratinocytes, and the chemotaxis of monocytes. The aim in the current study 
was to elucidate the phenotype of nemosis and its effects on tumor growth.  
 
The detailed aims were: 
1. To investigate the role of FN-integrin interaction and FN matrix 
assembly in the formation and activation of fibroblast spheroid. 
2. To determine gene expression changes in nemosis compared to adherent 
fibroblasts cultures. 
3. To uncover the phenotype that fibroblasts undertake during spheroid 
activation.  
4. To characterize the effects of spheroid-activated fibroblasts on tumor 
growth.  
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3. MATERIALS AND METHODS 
 
3.1 Cell culture (I-IV) 
 
Human foreskin dermal fibroblasts: HFSF (kindly provided by Dr. Magdalena 
Eisinger, Memorial Sloan-Kettering Cancer Center, New York, NY, USA) and 
CCD-1072sk (ATCC, Manassas, VA). Mouse embryonic fibroblasts: FN-/-, FNfl/fl 
(control for FN-/-), FNRGE/RGE and FNRGD/RGD (control for FNRGE/REG). Human 
fibrosarcoma cell lines: HT-1080 and AT9733 were cultured at +37o C in 5% CO2 
atmosphere in DMEM/F-12 medium (Invitrogen, Carlsbad, CA) supplemented 
with 5% Fetal calf serum (FCS; Invitrogen), 100 µg/ml streptomycin, and 100 
U/ml penicillin. HFSF cells were used at passages 10 to 25. FN-/- and FNRGE/RGE 
cells were previously described in references [187, 188]. 
Spontaneously immortalized HaCat human keratinocyte cell line and its 
variants (A5, II-4 and RT3), containing H-ras oncogene (Val 12 mutation), 
represent different stages of tumor progression. A5 clone is classified as benign, 
whereas II-4 clone forms well differentiated squamous cell carcinoma. The high-
grade malignant and metastasizing variant RT3 was generated by in vivo 
passaging of A5 clone [189]. HaCat, A5, II-4 and RT3 cells (kindly provided by 
Dr. Petra Boukamp and Dr. Norbert E. Fusenig, DKFZ, Heidelberg, Germany) 
were cultured in DMEM medium supplemented with 10% FCS (Invitrogen), 100 
µg/ml streptomycin, and 100 U/ml penicillin. 
Fibroblast spheroids were formed by plating 200 !l aliquots of cell 
suspensions (5x104 cells/ml) on agarose-coated U-bottom 96-well plates 
(Costar, Cambridge, MA). For LDH activity assay 100 µl cell suspension (20x104 
cells/ml) was plated per well. In some experiments, inhibitors, peptides, 
proteins or antibodies (Table 5) were added to the cell suspension before 
initiation of spheroid formation. To study the effect of FN-integrin interaction 
on spheroid formation and activation, the experiments were done using 1% FN-
depleted FCS. FCS was depleted of FN by incubating it with gelatin-Sepharose 
(Pharmacia, Uppsala, Sweden) overnight at +4 °C. The depleted FCS was sterile 
filtered through 0.2 µm filter (Millipore, Cork, Ireland). The removal of FN was 
confirmed by dot blotting.  
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3.1.2. Lentiviral mediated shRNA (II) 
 
293FT cells (Invitrogen) were transfected using Lipofectamine 2000 
(Invitrogen) together with pLKO.1 plasmid, expressing shRNA against ATG5 
and puromycin-resistance gene (Clone: TRCN0000151963; Open Biosystem, 
Huntsville, AL) or non-targeting scramble shRNA (Biomedicum Genomics, 
Helsinki, Finland), and packaging vector pCMV&8.91 and pHCMV-G, which 
express the vesicular stomatitis virus envelope glycoprotein G. After 48 h, the 
lentivirus-containing supernatant was collected and filtered (Millex-HV 0.45 µm 
low protein binding PVDH filter) (Millipore Corporation, Bedford, MA) to 
exclude carryover of 293FT packaging cells. HFSF cells were transduced with 
filtered supernatant containing 8 µg/ml polybrene (Sigma-Aldrich) overnight. 
After 48 h, tranduced cells were selected using puromycin (2 µg/ml) for five 
days.  
 
3.2 Functional assays 
 
3.2.1 Soft-agar assay (II) 
 
The soft-agar colony forming assay was done as described [178]. Briefly, 
adherent fibroblast cultures were plated on a 6 well plate (5 000, 50 000 or 500 
000 cells/well) one day before the experiment. The cells or empty wells 
(control) were overlaid with 0.5% low-melting point agarose (Invitrogen, 
Carlsbad, CA) in DMEM:F-12 supplemented with 5% FCS and antibiotics, and 
were allowed to solidify at +4 °C for 30 min. In spheroid groups, the indicated 
amounts of spheroids were mixed in the bottom agar, which was let to solidify. 
RT3 keratinocytes (5 000 cells/well) were mixed with 0.3% top agarose in 
DMEM:F-12 supplemented with 5% FCS and antibiotics, which was added to 
the bottom agar and let to solidify at +4 °C for 30 min (Figure 9). After the agar 
had solidified, the plates were placed in a standard cell incubator and 100 µl of 
growth medium was added once a week to prevent the agar from drying. All 
groups were done in duplicate and three images per well were taken at indicated 
times for analyzing the number and growth of colonies. The size of the colonies 
was quantified using NIH ImageJ software (http://rsb.info.nih.gov/ij/) [192]. 
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Figure 9. Soft-agar experimental setup 
 
3.2.2 Collagen co-culture assay (III) 
 
24-well plates were overlaid with 200 !l of ice-cold mixture containing rat tail 
collagen type I (80 !l; final concentration in lattice was 1.6 mg/ml) (Millipore, 
Cork, Ireland), 2xDMEM (100 !l) and DMEM (20 !l) and let to polymerize for 
30 min in the cell culture incubator. 45 human fibroblast spheroids (5-day old) 
were collected and diluted to 200 !l of ice-cold 2xDMEM. After a short 
incubation on ice 40 !l DMEM and 160 !l of ice-cold collagen were rapidly 
mixed with the spheroids and the mixture was overlaid on top of the first 
collagen lattice. Cell-free collagen- and fibroblast-collagen lattices were 
prepared by mixing ice-cold 2xDMEM (with or without 450 000 fibroblasts) 
(300 !l), DMEM (60 !l) and collagen (240 !l), and poured on a clean 24-well 
plate well. The collagen lattices were permitted to polymerize for additional 45 
min in the cell culture incubator, and 250 000 cells/well of HaCaT or RT3 cells 
were plated on top of the collagen lattice (Figure 10). After 6 days of incubation, 
the collagen lattices were fixed with cytoskeletal buffer with sucrose (4% 
paraformaldehyde, 320 mM sucrose, 10 mM MES, 138 mM KCl, 3 mM MgCl2, 2 
mM EGTA), permeabilized with 0.5% Triton X-100 in PBS and embedded in 
paraffin.  
 
 
Figure 10. Collagen co-culture experimental setup 
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3.2.3 Tumor xenograft models (II) 
 
In order to generate tumors, 6x105 RT3 cells alone, together with 3.6x105 
fibroblasts or with 36 spheroids were suspended in 100 µl of 1:1 dilution of PBS 
and growth factor reduced Matrigel (BD Biosciences), and injected to the 
peritoneal cavity of female Balb/c nude mice (Scanbur, Sweden). The tumors 
were measured using a calibre at indicated times and volumes were calculated 
using the following formula: Volume = 0.5 X height X width X length. The 
experiments in NOD/SCID (Charles Rivers Laboratories, Margate, U. K.) mice 
were conducted in a similar way, except the number of implanted cells was 
6x105 RT3 cells with either 3.2x105 fibroblasts or 32 spheroids.  
 
3.3. Protein expression (I-IV) 
 
3.3.1 Western blot (I-IV) 
 
The spheroid and monolayer cultures were lysed in reducing Laemmli sample 
buffer and incubated at +100 °C for 5 min. Protein extracts were separated by 8 
to 20% gradient SDS-PAGE and transferred to nitrocellulose membranes. 
Unspecific binding was blocked with 2.5% powdered non-fat milk in 20 mM 
Tris-HCl pH 7.5, 150 mM NaCl and 0.1% Tween-20. Immunoreactive proteins 
were visualized with the appropriate primary and secondary antibodies using 
ECL detection (Pierce, Rockford, IL). The densiometric analysis of the films was 
done using NIH ImageJ software.  
 
3.3.2 Immunohistochemistry, immunofluorescence and senescence-
associated #-galactosidase (I-IV) 
 
Spheroids were collected at the indicated times, snap frozen in liquid nitrogen 
and embedded in OCT (Tissue Tek, Sakura Finetek Europe B.V., Zoeterwoude, 
NL). For tumors, the samples were collected immediately after the sacrifice and 
fixed with 4% paraformaldehyde solution for 1 hour, soaked in 30% PBS-sucrose 
overnight, embedded in OCT and frozen in the freezer. Eight-µm frozen sections 
were cut, fixed with freezer-cold acetone and stained with the indicated 
antibodies. For paraffin-embedded spheroid and tissue blocks, the samples were 
fixed with 4% paraformaldehyde (spheroids for 1 hour and tumor overnight), 
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dehydrated and embedded to paraffin blocks. Immunohistochemistry (IHC) was 
performed with the Ventana Discovery immunohistochemistry Slide Stainer 
(Ventana Medical Systems, Inc., Tucson, AZ). Paraffin-embedded 5-!m sections 
of spheroids were incubated with primary antibodies for 32 min each. The 
staining was performed with the Ventana 3,3'-diaminobenzidine 
tetrahydrochloride (DAB) biotin avidin detection kit. 
SA-#-gal activity was detected as described in [164]. Briefly: whole 
spheroids, frozen sections or monolayer cultures were fixed with 2% PFA/0.2% 
glutaraldehyde in PBS for 5 min, washed and incubated with staining buffer (1 
mg/ml X-gal, 150 mM NaCl, 2 mM MgCl2, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6 in 
40 mM phosphate buffer pH 6) overnight. In SA-#-gal and IHC double staining, 
frozen sections were stained first with SA-#-gal and then stained using 
antibodies with Ventana Discovery immunohistochemistry Slide Stainer. 
 
3.3.3 Enzyme-linked immunosorbent assay (ELISA) (IV) 
 
The concentrations of VEGF and HGF in the culture media were determined 
using ELISA assays (R&D Systems for HGF and Orgenium Laboratories for 
VEGF) according to manufacturers’ instructions. 
 
3.3.4 LDH activity assay (II, III) 
 
Media from fibroblast spheroids were collected at the indicated times and 
clarified by centrifugation at 5 000 x g for 5 min. LDH activity was measured 
using colorometric assays (Cayman Chemicals (II) or Roche (III)). Aliquots of 
100 µl of medium were mixed with 100 µl of LDH assay buffer, incubated for 30 
min and optical density was measured at 492 nm.  
 
3.3.5 Caseinolysis assay 
 
Proteolytic activity in fibroblast spheroid-conditioned medium was quantified 
using radial caseinolysis assays [193]. Aliquots of 10 µl of spheroid-conditioned 
medium were added to the wells of an agarose gel containing 1% casein. The gels 
were incubated at +37 °C for 72 h and the lysis zones were measured. 
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3.4.3 Microarray 
 
Total RNA was extracted from the corresponding adherent and spheroid 
cultures 3, 12, 24 and 36 h after seeding by standard methods using Trizol 
Reagent (Invitrogen) followed by purification with the RNeasy kit according to 
the manufacturer’s instructions (QIAGEN). RNA quality was assessed by using 
the Agilent Bioanalyser 2100 (Agilent Technologies, Palo Alto, CA).  
Biotinylated cRNAs were prepared from 5 !g of total RNA for hybridization 
according to the manufacturer’s instructions (Affymetrix, Santa Clara, CA). 
Briefly, RNA was converted to first-strand cDNA by the use of a T7-(dT)24 
primer (Invitrogen), followed by second-strand synthesis (Invitrogen). This 
double-stranded cDNA then served as a template for labeling the in vitro 
transcripts using biotinylated ribonucleotides (Enzo, Farmingdale, NY). Fifteen 
!g of each labeled cRNA was chemically fragmented and then hybridized to 
Affymetrix HG-U133A GeneChips under standard conditions in an Affymetrix 
fluidics station. To eliminate false-positive results, duplicate samples and chips 
were performed for both adherent and spheroid cultures at 36 hours.  
 
3.4.3.1 Microarray data analysis  
 
The arrays were scanned according to the manufacturer's instructions 
(Affymetrix). Obvious artifacts and the outliers on the scanned images were 
excluded from the analysis by Affymetrix® Microarray Suite 5.0 software.  
The gene expression profiles of adherent and spheroid cultures were 
compared by means of the GeneSpring™ software version 7.2 (Agilent 
Technologies). The data were normalized by GC-RMA normalization and per 
gene: Normalize to median. The "Cross gene error model for replicates" was 
active. Those transcripts that were not at least 2-fold upregulated or 
downregulated compared to adherent cultures, whose normalized values were 
under 2 (as 2-fold upregulated) and over 0.5 (as 2-fold downregulated), or were 
not given a present tag by Affymetrix® Microarray Suite 5.0 (MAS5.0) at 36 h 
(either in adherent or spheroid cultures) were removed from the statistical 
analysis. The decision on the present tags was made based on the present and 
absent tags generated by MAS5.0, expecting that the transcript was present in 
both replicates in monolayer or spheroid samples. Significantly (p "0.05) 
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upregulated or downregulated transcripts were determined by comparison of 
adherent and spheroid cultures at 36 h using student’s t-test and the Benjamini 
and Hochberg False Discovery Rate as a multiple testing correction. The data 
are deposited at http://www.ebi.ac.uk/arrayexpress/, accession number: E-
MEXP-1226. 
 
3.5 Fluorescence-activated cell sorting (FACS) (II) 
 
For cell cycle analysis the cells were dissociated from the spheroids or from 
monolayers with trypsin-EDTA and fixed with 70% ethanol at least overnight. 
The cells were washed once with PBS and stained 10 min with propidium iodide 
(10 µg/ml for 10 min at room temperature) (Invitrogen) and analyzed with 
FACScanner (BD Biosciences)  
 
3.6 Transmission electron microscopy (TEM) (II) 
 
The spheroids were collected at the indicated time points and fixed with 2.5% 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), washed with phosphate 
buffer and fixed again with 2% osmium tetroxide. After washing the spheroids 
were dehydrated with Ethanol gradient and embedded into Epoxy resin LX-112. 
The epon blocks were cut into ultrathin (80 nm) sections, and stained with 
uranyl acetate and led citrate. Electron microscopy was performed using JEOL 
1400 TEM (JEOL, Tokyo Japan) at 80 kV. 
 
3.7 Statistical analyses 
 
SPSS software was used to calculate statistical significances. 
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4. RESULTS AND DISCUSSION 
 
4.1 Fibronectin-integrin interaction is required for 
fibroblast spheroid formation and activation (I) 
 
Nemotic fibroblasts have been shown to produce a variety of interesting 
inflammation and tumor-associated secretory factors, and the paracrine 
signaling mediated by these factors to other cell types is relatively well 
characterized in vitro. However, nothing is known about the molecules that 
mediate the formation of fibroblast spheroids or cellular processes that lead to 
nemotic activation. In this study, we sought to investigate the molecules that 
participate in the initial formation of fibroblast spheroids.  
 
4.1.1 Effect of fibronectin on spheroid formation (I) 
 
FN started to accumulate in fibroblast spheroids already 3 h after the initiation 
of spheroid formation and its amount began to decline after 24 h, indicating an 
induction of proteolytic mechanisms in the spheroids (Figure 1A and 1B in I). 
This is in agreement with activation of FN-degrading plasminogen in fibroblast 
spheroids [176, 194]. As expected, cycloheximide, an inhibitor of translation 
[195], prevented the accumulation of FN, but at the same time resulted in 
looser-structured spheroids. Adding exogenous pFN counteracted this effect 
and resulted in more compact spheroids, suggesting that FN is needed for the 
formation of tight spheroids (Figure 1B, 1C and 1D in I).  
This observation was further tested using immortalized mouse embryonic 
fibroblasts where the FN gene was knocked-out (FN-/- cells) or its integrin 
binding RGD motif was mutated to RGE (FNRGE/RGE cells). Both of these cell 
lines resulted in more loosely-structured spheroids and adding pFN restored the 
formation of tight spheroid structures (Figure 2A and 2C in I). This confirmed 
that FN mediates the formation of fibroblast spheroids and suggested that the 
integrins mediate this interaction through the FN’s integrin binding motif RGD.  
To investigate whether FN protein mediated spheroid formation is 
necessary for nemotic activation as well, we used siRNA to deplete FN from 
primary human skin fibroblasts. FN siRNA -treated fibroblast spheroids 
expressed only a residual amount of FN protein and were unable to induce 
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COX-2, considered to be a marker of nemotic activation, in response to spheroid 
formation. Unexpectedly, adding pFN to the forming fibroblast spheroids did 
not restore the induction of COX-2 (Figure 2E in I). This suggests that although 
the addition of pFN can counteract the deletion of FN synthesis in spheroid 
formation, the activation of fibroblasts requires that FN be produced in the cells 
themselves, or alternatively spliced cFN is needed.  
To further elaborate the role of the FN-RGD-motif on activation of 
fibroblast spheroids we used the hexapeptide (GRGDSP) and an inactive 
control peptide (GRGESP) to stimulate spheroids during formation. GRGDSP 
peptide was able to prevent spheroid formation and FN accumulation, but also 
augmented COX-2 induction (Figure 3D and 3E in I), considered a hallmark of 
nemotic activation [176], indicating that it can function as a competitive peptide 
for FN, and that fibroblast activation is mediated via the RGD motif.  
 
4.1.2 FN-integrin interaction and FN matrix formation in fibroblast 
spheroids (I) 
 
As shown above FN’s integrin binding motif RGD plays an important role in the 
spheroid formation and activation. We characterized FN-binding integrins more 
closely using antibodies that prevent FN adhesion to a particular integrin 
subunit. We focused on !5, !V and #1 integrin subunits, as those were the 
highly expressed ones in fibroblasts according to microarray data. Antibodies 
against !5 and #1 integrins were able to retard spheroid formation, whereas !V 
integrin did not have any effect (Figure 3A and 3B in I). On the contrary, !V and 
#1 integrins inhibited COX-2 induction whereas !5 integrin did not have an 
effect (Table 7, Figure 3C in I). This might be due to the fact that the antibody 
we used has been shown to act as an activating ligand for !5 integrin [196]. 
The binding of RGD to integrin is enhanced by the synergy sequence 
PHSRN located between the 9th and 10th type III repeats in FN molecule (Figure 
2) [197]. FN binding to integrins also activates FN matrix formation [53]. To 
study the effect of synergy site and FN matrix on spheroid formation, we used a 
FN antibody that targets FN in the same site where the synergy site is located 
and in addition, we also used a 70 kDa N-terminal fragment of FN, which has 
been shown to prevent FN matrix formation [198]. Interestingly, both 
treatments delayed spheroid formation, but did not affect the amount of FN in 
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These results are in agreement with other studies showing that integrin 
!5#1 regulate FN matrix deposition and strong compaction of Chinese hamster 
ovary (CHO) B2 cell spheroids that where engineered to express !5#1 integrin 
[60, 204, 205]. These studies also showed that fibronectin matrix deposition is 
essential to mediate strong cell-cell cohesion in spheroid, whereas in our setup 
inhibition of matrix deposition by 70 kDa FN fragment delayed spheroid 
formation only marginally. The difference might be due to the cell types used. 
The surface of normal fibroblasts is rich in a variety of integrins, whereas CHO 
B2 lacks the integrin !5 subunit and is not able to bind FN [206], indicating that 
other subunits are not able to compensate FN binding in CHO B2 cells. Hence, 
other integrin subunits could counteract !5#1 integrin mediated FN matrix 
deposition in normal fibroblasts.  
It is well established that activated fibroblasts (myofibroblasts) produce FN 
EDA splice variant [12]. This is in line with our result showing that fibronectin-
integrin interaction is required for the activation of fibroblast spheroids. 
Furthermore, adding pFN that lacks EDA domain was not able to rescue the 
activated phenotype of FN depleted fibroblast spheroids. In addition cell 
adhesion to fibronectin induces and stabilizes COX-2 protein [207, 208], as well 
as activates inflammatory-associated transcription factor NF-"B [209, 210]. 
 
4.2 Gene expression changes in fibroblast spheroids 
compared to adherent fibroblast cultures (II) 
 
To tentatively characterize the phenotype that cells acquire in fibroblast 
spheroids, we performed genome-wide gene expression microarray analysis 3, 
12, 24 and 36 h after the initiation of spheroid formation. The change in gene 
expression within time is shown in figures S1A and S1B in II. An independent 
duplicate analysis at the 36 h time-point revealed a massive changes in gene 
expression compared to standard adherent cultures. Over 16% of genes 
expressed in fibroblast spheroids had altered expression levels compared to 
adherent fibroblasts. When the list of up- and downregulated genes was 
categorized according to their Gene Ontologies, the change could be roughly 
divided into three groups: Most of the upregulated genes encoded secreted 
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conversion of LC3B-I to LC3B-II form, a universally used marker of autophagic 
vacuoles. LC3B-II appeared already 1.5 h after the initiation of spheroid 
formation. After 12 h both forms, LC3B-I and LC3B-II started to decline, 
indicating active autophagy (Figure 3B in II). The expression of LC3B-II 
correlated with the expressions of p62 and polyubiquitinated proteins (Figure 
3B in II). During induced autophagy p62 becomes incorporated to 
autophagosome and is degraded completely [211]. There is a marginal induction 
of p62 in fibroblast spheroids, peaking at 12 h after the initiation of spheroid 
formation, and after that its level starts to decline, although it never disappears 
completely (Figure 3B in II). The initial induction of p62 protein is explained by 
the induction of p62 mRNA (12 fold in microarray analysis) in fibroblasts 
spheroids. The disappearance of polyubiquitinated proteins and the decline of 
p62 suggest that autophagy was induced in fibroblast spheroids.  
To confirm the induction of autophagy we used shRNA against ATG5, as 
well as two inhibitors, 3-MeA, which prevents autophagosome formation, and 
bafilomycin A1 (Baf A1), which prevents the lysosomal acidification, to block 
autophagy at different steps of the process. The formation of LC3B-II was 
almost completely blocked in response to ATG5 shRNA (Figure 4A and 4B in II). 
It was not entirely effective in preventing the degradation of LC3B-I and p62 
(Figure 4A and 4B in II), suggesting that a residual amount of ATG5 is active or 
that the proteins are also degraded in an alternative process in fibroblast 
spheroids. 3-MeA inhibited the formation of LC3B-II for 3 h, but after this it 
was ineffective in blocking the formation of LC3B-II (Figure 4A and 4B in II). 
This is because the ability of 3-MeA to inhibit class III PI3K is only transient and 
it lasts only less than 6 h [212]. Nonetheless, 3-MeA was able to decrease the 
degradation of LC3B-II and p62, proposing that it is inhibiting autophagic flux 
in fibroblast spheroids. The lysosomal inhibitor Baf A1 blocked autophagic flux 
completely, as evidenced by the accumulation of LC3B-II and p62 (Figure 4A 
and 4B in II). Baf A1 prevents the acidification of lysosomes and other vesicles, 
as well as the fusion of autophagosome and lysosome [213]. The accumulation of 
LC3B-II and p62 in fibroblast spheroids treated with Baf A1 indicates that 
autophagy is induced during spheroid formation and that the increase in 
autophagosomes is not due to reduced turnover of autophagosomes and 
autolysosomes.  
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The induction of autophagy happens approximately at the same time as FN-
integrin interaction mediates spheroid formation. This is contrary to other 
studies showing that disintegrated integrins signal to induce autophagy during 
cell detachment from ECM to provide cell survival against anoikis [214]. 
However, recently it was found that the plasminogen activator inhibitor-1 and -
2-mediated remodeling of ECM causes autophagy dependent fibroblast 
activation [215]. This may explain the discrepancy in FN-integrin interaction 
and induction of autophagy.  
The inhibition of autophagy, using ATG5 targeted shRNA, caused cell death 
as measured by the increased release of LDH in culture media (Figure 4C in II). 
This is in agreement with numerous studies showing autophagy as a survival 
mechanism against various stress conditions [216]. Usually the inhibition of 
stress induced autophagy leads to enhanced apoptic response [216]. 
Interestingly, shATG5-mediated cell death in fibroblast spheroids was not 
associated with increased cleaved-caspase-3, cleaved-caspase-8 or cleaved-
PARP (the activated forms of these proteins) (unpublished data), indicating that 
the inhibition of ATG5 does not induce apoptosis in fibroblast spheroids. This is 
in agreement with the findings that the inhibition of autophagy induces necrosis 
in apoptosis impaired cells [117, 118], and that fibroblast spheroids seem to 
actively avoid apoptosis by downregulating apoptosis regulators and 
upregulating anti-apoptotic molecules, such as NF-"B, COX-2, PAI-2 and HGF 
[176, 177, 179]. 
 
4.3.1 ERK and Akt as possible regulators of autophagy in fibroblast 
spheroids (II) 
 
A major negative regulator of autophagy is the mammalian target of rapamycin 
(mTOR), which senses environmental signals and controls cell growth and 
proliferation [77]. These signals are conveyed by Akt, which in turn regulates 
mTOR activity [217]. In fibroblast spheroids Akt was dephosphorylated, 
indicating inactivation, already after a few hours after the initiation of spheroid 
formation as shown by the immunoblot (Figure 3C in II). This suggests that the 
induction of autophagy might be mediated by the negative regulation of Akt and 
the subsequent inactivation of mTOR in fibroblast spheroids, although 
additional experimentation is needed to evidence its direct role. The 
 - Results and discussion - 
52 
dephosphorylation of Akt was timely associated with the fibronectin-integrin 
mediated spheroid formation. This is somewhat contrary to the integrin 
mediated Akt activation in response to fibronectin adhesion [218], but 
strengthen the conclusion that FN-integrin interaction leads to unusual signal 
transduction.  
Another well-known mediator of extracellular signals is the extracellular 
signal-regulated kinase (Erk). Its activity is regulated by mitogens. Erk was 
transiently (between 1.5-12 h) activated in fibroblast spheroids as shown by the 
increase of the phosphorylated form in the immunoblot (Figure 3C in II). Erk 
participates in the regulation of autophagy [219], but its role as a regulator of 
autophagy is not as straightforward as Akt’s. To explore its effects on spheroid-
induced autophagy we used mitogen-activated protein kinase kinase 1 and 2 
(MEK1/2) inhibitor U0126 [220]. MEK1/2 is located upstream of ERK and 
regulates its activity through phosphorylation [221]. As expected, 20 µM U0126 
efficiently blocked ERK phosphorylation (Figure S4C in II). The stimulation of 
spheroids with U0126 also decreased the formation of LC3B-II and degradation 
of LC3B-I and p62 (Figure 4A and 4B in II), suggesting that ERK might mediate 
the induction of autophagy in fibroblast spheroids.  
ERK conveys signals of many growth factors and cytokines that negatively 
regulate autophagy [219]. In this study ERK inhibition resulted almost complete 
inhibition of LC3B-II formation. Whether this is a direct effect of ERK on the 
formation of autophagosome, or an indirect effect on other molecules, remains 
unsolved. Interestingly, ROS have been shown to mediate the induction of 
autophagy through ERK activation [222]. 
 
4.4 The downregulation of cytoskeleton is associated with 
fibroblast spheroid formation (II) 
 
Another distinct feature from TEM analysis was a clear decrease in cytosol 
volume (Figure S3 in II). Furthermore, when the changes in the gene expression 
of fibroblast spheroids were compared to adherent fibroblast cultures using 
gene expression microarrays, it became clear that the genes associated with the 
cytoskeleton were downregulated (Figure 1A in II). Immunoblot analysis 
confirmed the downregulation of the cytoskeletal proteins actin and #-tubulin 
also at protein level (Figure 1G in II). The smaller cell size was also visible in the 
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phase-contrast microscopy and FACS analysis (Figure 1F and 11D in II). To 
study whether autophagy participated in the cell-size shrinkage, we measured 
how the above-mentioned autophagy inhibitors affected fibroblast size in 
spheroids. Forming spheroids were treated with the inhibitors (3-MeA, Baf A1, 
U0126, shATG5) for 48 h. The cell size was determined by taking images of cells 
using phase-contrast microscopy and the cell area was estimated using ImageJ 
–software. The cells in spheroids treated with the inhibitors were significantly 
larger than the control cells in untreated spheroids (Figure 4D and 4E in II), 
indicating that the shrinkage of cytosol was due to the degradation of cytosolic 
components through autophagy and the downregulation of the expression of 
cytoskeletal proteins.  
Cytoskeleton plays an important role in the function of myofibroblasts. 
Fibroblasts are able to convey signals from changed ECM structure through 
contractile actin cytoskeleton to regulate gene expression in a process called 
mechanotransduction [223]. The reason why nemotic fibroblasts downregulate 
their cytoskeleton is still unclear, but it has been shown that cells downregulate 
their cytoskeleton in response to stress [100], and it has been suggested that 
cytoskeleton needs to be degraded to achieve efficient remodeling of cell 
structure when cells change their phenotype [224]. Interestingly, stressed 
cancer cells have been shown to shrink in autophagy-dependent manner to the 
state of reversible dormancy [225, 226]. Proliferation of dormant cells is 
arrested in quiescence state in a new microenvironment, and the dormant cells 
are resistant to stress and therapy induced cell death [227, 228].  
 
4.5 Fibroblast spheroid formation relates to cell cycle 
arrest (II) 
 
Microarray experiments also revealed that fibroblast spheroids are associated 
with the universal downregulation of genes associated with the cell cycle, 
suggesting a decrease in cellular proliferation (Figure 1A in II). To confirm this, 
we analyzed the expression of proliferation markers, such as proliferating cell 
nuclear antigen (PCNA) and Ki67. As expected on the basis of the microarray 
analysis, the expression of PCNA started to decline 24 h after the initiation of 
spheroid formation as shown by immunoblotting (Figure 1B in II). Ki67 
expression correlated with PCNA and the only proliferating cells were found in 
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the outermost layer of fibroblast spheroids as show by immunofluorescence 
with Ki67 antibody (Figure 1C in II). FACS analysis of the DNA content of cells 
indicated that the cells are arrested at G1/G0 cell cycle phase (Figure 1D in II).  
The most important cyclins that regulate the cell cycle progression in 
different phases (Cyclin A2, B1, B2 and E2) were downregulated according to 
the microarray analysis. Furthermore, cyclin D1 protein expression was also 
downregulated 24 h after the initiation of spheroid formation (Figure 1E in II). 
This indicates that the cells were rather withdrawn from the cell cycle than 
actually arrested. This observation was further strengthened by the finding that 
CDI p27 was induced at the same time when cyclin D1 was downregulated 
(Figure 1E in II). The simultaneous upregulation of p27 and downregulation of 
cyclin D1 are considered to be markers of cellular quiescence [229]. Cellular 
quiescence can be effectively induced by the loss of anchorage, contact 
inhibition or growth factor deprivation in fibroblasts [159].  
 
4.6 Spheroid-activated fibroblasts acquire secretory 
phenotype (II-III) 
 
Based on microarray data, the change in the gene expression profile of fibroblast 
spheroid vs. adherent fibroblast cultures could roughly be divided in three 
categories, to the previously mentioned downregulated cytoskeleton- and cell-
cycle-associated genes and the upregulation of genes that encode secretory 
proteins (Figure 1A in II). This is in agreement with our previous studies 
showing the induction of various cytokines and growth factors in response to 
spheroid formation, as well as paracrine effects mediated by these factors on 
other cell types. Interestingly, this secretory phenotype was very similar to 
SASP, which is seen in cellular senescence [172].  
 
4.7 Fibroblast spheroids express markers of senescence 
(II) 
 
Taken together, the fibroblast in spheroids are associated with similar features 
as the senescent cells, such as a secretory phenotype, increased lipofuscin and 
decreased proliferation. To determine whether cellular senescence is induced in 
response to spheroid formation, we analyzed common hallmarks of senescence. 
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Activity of SA-#-gal was induced 24 h after the initiation of the spheroid 
formation (Figure 2C in II). SA-#-gal activity is considered to be a marker of 
cellular senescence, although increased activity is also found in confluent 
fibroblast cell cultures [164]. Moreover, SA-#-gal activity reflects lysosomal 
mass [230], which is in agreement with our TEM findings, showing increased 
amount of autolysosomes. Unexpectedly, cell cycle inhibitors (p53, p21 and RB) 
that regulate cell cycle arrest in senescence, were all downregulated in fibroblast 
spheroids (Figure 2D in II).  
Furthermore, when the cells of 96-h-old fibroblast spheroids were dispersed 
using trypsin and plated as standard monolayer culture, they resumed cell 
proliferation as seen by the increased cell number and restoration of PCNA 
expression (Figure 2E in II). These cells also restored their actin expression, 
suggesting that the expression of cytoskeletal proteins was normalized (Figure 
2E in II). In addition, the expression of the stress proteins COX-2 (Figure 2E in 
II) and IL-6 (data not shown) disappeared suggesting the reversal of the 
secretory phenotype. Quiescent cells are considered to be passive, non-active 
and resting, although recently it was shown that they maintain high metabolic 
activity [161]. Our results indicate that in addition to metabolic activity 
quiescent cells can also harbor a secretory phenotype. 
Interestingly, cell cycle arrest and secretory phenotype seen in nemosis 
seem to be very similar to cellular senescence. In senescence cell cycle arrest is 
controlled by induction of CKI, such as p21, p53 and RB, and at the same time 
the expression of cyclins remains high [231], whereas in nemosis there is 
universal downregulation of cell cycle associated genes, indicating that 
fibroblasts in spheroids are withdrawn from the cell cycle to quiescence. 
Although nemosis relates to quiescence, secretory phenotype suggests that there 
is a simultaneous stress response that resembles senescence. Recently, it was 
shown that rapamycin, the inhibitor of mTOR, shifts p53 or p21 induced 
senescence to quiescence [232].  
The most compelling evidence that nemosis is not associated with 
senescence was that the nemotic phenotype was found to be reversible. 
Senescence is considered always to be an irreversible cell cycle arrest, although 
there are some studies suggesting that senescence could also be reversible. 
 - Results and discussion - 
56 
However, in these studies reversibility was achieved only by genetic inactivation 
or depleting of p53 in senescent cells where p16 expression was low [233, 234]. 
 
4.8 Nemotic fibroblasts secrete matrix metalloproteinases 
to modulate their environment (III) 
 
Plasmin is known to function as a major extracellular proteolytic system in 
fibroblast spheroids [176]. We wanted to characterize other possible proteolytic 
mechanisms to better understand the role of nemosis in the tumor 
microenvironment. According to the microarray results of fibroblast spheroids, 
matrix metalloproteinases (MMPs)-1, -10 and -14 (MT1-MMP) were induced 
5.8, 106 and 5.6-fold, respectively (Table I in III). Fibroblast spheroids also 
secreted these MMPs to their culture media as shown by immunoblotting 
(Figure 1A, 1B, 1C in III). MT1-MMP, which is bound to cell membranes, was 
also found in fibroblast spheroids (Figure 1E in III). These same MMPs that 
fibroblast spheroids produce are overexpressed in tumor stroma [235-237].  
The inhibition of MMP activity by pooled specific MMP inhibitors (CMT-3, 
CMT-5 and CMT-308) decreased LDH release by 11% and when combined with 
the broad-spectrum proteinase inhibitor, aprotinin, the LDH release was 
decreased by 21%. This indicates that nemosis-induced proteases, MMPs and 
plasmin, mediate the membrane damage related to nemosis. Proteinase activity 
was confirmed by using the casein-agarose assay. In this assay, ilomastat, an 
inhibitor of MMPs, inhibited casein degradation caused by fibroblast spheroid, 
indicating that spheroid mediated proteolytic activity was mediated by MMP 
activity. Suggesting that MMPs may also participate in the degradation of FN 
(Figure 1A in I). MMP-mediated degradation of ECM leads to increased cytokine 
and chemokine production [238], suggesting that MMP might functions as 
autocrine stimulators of inflammation response seen in fibroblast spheroids. In 
addition to degradation, MT1-MMP regulates endocytosis of non-polymerized 
fibronectin [239]. 
Unexpectedly, we did not find any activation of uPA and tPA, in the 
conditioned media of the spheroids. Although in situ hybridization indicated 
increased uPA and tPA mRNA in fibroblast spheroids, IHC showed no increase 
in uPA and tPA protein levels at the different time points in fibroblast spheroids 
(Figure 2 in III).  
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Nemosis expressed MMPs, together with previously published plasmin, are 
important mediators in cancer progression and inflammation. They modulate 
ECM, activate growth factors, such as TGF-#, promote angiogenesis, and assist 
invasion and metastasis by the degradation of basement membranes. In 
addition, they play a key role in the molecular communication between tumor 
and stroma, by processing cytokines to influence many inflammatory pathways 
[240, 241]. Although the expression of MMPs in tumors was long thought to 
only promote cancer growth and metastasis, clinical trials with specific MMP 
inhibitors yielded mostly negative results [242]. Moreover, new experimental 
data on the protective role of MMP activity in tumor progression has started to 
accumulate [243, 244]. It seems that most of protective role come from MMPs 
that are expressed in stromal cells [243]. 
 
4.9 Benign keratinocytes inhibit, whereas malignant 
keratinocytes promote nemotic activation (IV) 
 
Tumor cell derived conditioned medium causes adherent fibroblast cultures to 
spontaneously form spheroid structures [177, 178]. This finding led us to further 
characterize tumor cell mediated paracrine effect on nemotic fibroblasts. We 
used a cell panel of HaCaT-keratinocytes representing different stages of tumor 
progression from immortalized to high-grade malignant, metastasizing cells. We 
stimulated the forming fibroblast spheroids with conditioned medium from 
different HaCaT cell clones and analyzed the expression of COX-2 by 
immunoblotting, and HGF and VEGF growth factors by ELISA and qRT-PCR. 
IHC was used to evaluate markers of activated fibroblasts, !-SMA and vimentin. 
Conditioned medium from benign HaCaT clones (parental HaCaT and A5) 
inhibited COX-2 expression, whereas medium from II-4 keratinocytes had no 
effect and metastasizing RT3-cell-conditioned medium enhanced COX-2 
induction in fibroblast spheroids (Figure 1A and 1B in IV). This indicated that 
benign cells produce anti-nemotic factors whereas malignant cells produce pro-
nemotic factors. Further characterization of these factors may reveal new 
therapeutic targets for the treatment of inflammation. To test whether these 
factors are able to overrule each other, we added 25% of RT3-conditioned 
medium to HaCaT-conditioned medium. This treatment was able to restore 
 - Results and discussion - 
58 
COX-2 expression and vice versa, adding HaCaT conditioned medium was able 
to prevent the effect of RT3-conditioned medium (Figure 4A and 4B in IV).  
In carcinogenesis, COX-2 is linked to tumor progression, inflammation and 
angiogenesis [245, 246]. Other important mediators of tumor angiogenesis are 
HGF and VEGF, which are also upregulated in fibroblast spheroids [177, 178, 
182]. Therefore, we examined their secretion from nemotic fibroblasts in 
response to HaCaT clones. Spheroids secreted 60-fold more HGF and 6-fold 
more VEGF on protein level than adherent fibroblast cultures after 72 hour 
incubation (Figure 2A in IV). This was also reflected at the mRNA levels with 
10- and 2-fold increased expression of HGF and VEGF mRNA, respectively 
(Figure 2B in IV). All HaCaT clones further stimulated the secretion of HGF and 
VEGF from fibroblast spheroids, but only Ras-transformed HaCaT cells (A5, II-
4 and RT3) significantly increased HGF secretion (Figure 2A and 2D in IV), 
further strengthening the observation that malignant cells promoted nemotic 
response of fibroblasts.  
To further characterize the effect of HaCaT and RT3 cells on fibroblast 
spheroids, we performed co-culture experiments. Spheroids were embedded in 
collagen type I and adherent keratinocyte cultures were seeded on top of the 
collagen lattice. HaCaT cells stimulated the outgrowth and migration of 
fibroblasts from spheroids more than malignant RT3 keratinocytes (Figure 5A 
in IV). We also observed increased degradation of collagen around fibroblast 
spheroids in the cultures containing RT3 cells (Figure 5D, 5F and 5H in IV), 
suggesting increased expression of proteases in fibroblast spheroids in response 
to RT3 cells. This is in agreement with the earlier observations of increased 
MMP production in fibroblasts in co-culture with keratinocytes [247-249]. To 
confirm that the malignant RT3 cells promote nemosis in co-culture assays, 
similar to their conditioned medium, we used IHC to stain COX-2 in fibroblast 
spheroids (Figure 5C and 5D in IV). In agreement with the immunoblotting 
results, the co-culture with RT3 keratinocytes induced strong COX-2 staining, 
whereas the co-cultures with HaCaT cells gave only faint staining in fibroblast 
spheroids. We also detected increased !-SMA and decreased vimentin staining 
in the fibroblasts spheroids in RT3 co-cultures compared to HaCaT co-cultures 
(Figure 1E, 1F, 1G and 1H in IV), indicating myofibroblastic differentiation of 
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nemotic fibroblasts in response to malignant RT3 keratinocytes. Thus, our 
results further extend previous findings that malignant cells activate fibroblasts.  
 
4.10 Fibroblast spheroids inhibit growth of malignant 
keratinocytes (II) 
 
Nemotic fibroblasts increase cancer cell motility, invasiveness and proliferation 
in cell culture experiments, but are also able to induce differentiation of c-Met-
negative leukemia cells. Furthermore, as shown above, malignant keratinocytes 
(RT3) promote the nemotic response of fibroblasts. To further study the effect of 
this paracrine signaling on RT3 cells we measured the ability of RT3 cells to 
form colonies in soft-agar co-culture with fibroblast spheroids. We also used a 
mouse xenograft model to measure the growth of RT3 tumors in vivo. 
 
4.10.1 RT3 cell growth on soft-agar is attenuated by co-culture with 
fibroblast spheroids (II) 
 
To study how fibroblast spheroids impact the anchorage-independent growth of 
RT3 cells, we plated different amounts (6, 12, 32, 96 or 180 spheroids) of 
fibroblast spheroids in the bottom agar and RT3 keratinocytes in top agar of soft 
agar cultures. Fibroblast spheroids stimulated the growth of RT3 colonies 
during the first eight days. This stimulation was dependent on the number of 
spheroids plated in the agarose (Figure 6A in II). When the experiment 
progressed the higher numbers (over 32) of spheroids started to have an adverse 
effect on the RT3 colonies (Figure 6B and 6D in II). The colonies changed their 
shape from spherical to irregular and appeared as decomposed. High number of 
fibroblast spheroids also lost the ability to stimulate the growth of RT3 colonies 
as measured as an increase in their size. Fibroblast spheroids had no effect on 
the number of RT3 colonies (Figure 6C in II).  
Fibroblast spheroids are able to stimulate the proliferation and motility of 
adherent RT3 cells [186]. Our results are in line with this. Small numbers of 
fibroblast spheroids stimulated the growth of RT3 colonies in soft agarose, 
whereas higher numbers had deleterious effects on RT3 cells in soft agarose. 
The concentration of paracrine factors secreted in nemosis may explain this 
difference. Cells are also known to behave differently when they are cultivated in 
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a 3-dimensional environment, such as soft agarose, compared to 2-dimensional 
standard cell culture conditions.  
 
4.10.2 Fibroblast spheroids attenuate the growth of xenograft 
tumors by inducing tumor cell senescence (II) 
 
In addition to direct effects on cancer cells, nemotic fibroblasts may have effects 
on other stromal cell types in tumors. To better elucidate the impact of nemotic 
fibroblast spheroids on the progression of tumors, we injected RT3 
keratinocytes together with adherent fibroblast cultures or fibroblast spheroids 
to the peritoneal cavity of female Balb/c nude or NOD/SCID mice. Fibroblast 
spheroids significantly reduced the RT3 tumor growth compared to control RT3 
tumors or RT3 tumors containing monolayer-cultivated fibroblasts. This was 
seen as a reduction of both tumor size and tumor weight (Figure 7A, 7B, S6A 
and S6B in II).  
The slower tumor growth was associated with an increase in SA-#-gal 
staining in tumor sections (Figure 6C in II), suggesting an induction of tumor 
cell senescence. This observation was further strengthened by the simultaneous 
upregulation of p14ARF and downregulation of p63 in these same SA-#-gal 
positive areas (Figure 7D in II). The upregulation of p14ARF induces cellular 
senescence and its upregulation depends on the downregulation of p63 [250]. 
Remarkably, RT3 cells harbor a mutation in p53 gene enabling them to escape 
classical p53-mediated senescence. The induction of p14ARF can mediate 
senescence by both p53-dependent and independent mechanisms [251, 252]. 
In addition to the induction of senescence, fibroblast spheroids caused 
cytokeratin-7 mediated differentiation in RT3 tumors (Figure 7F in II). This is in 
agreement with previous publications showing close connection between 
cytokeratin-7 mediated differentiation and tumor senescence [253, 254]. This 
finding is also in line with the differentiation of KG-1 and THP-1 cells in 
response to nemotic fibroblasts [181]. Although nemotic fibroblasts stimulate 
the growth and invasion of cancer cell in vitro, our results show that the 
complex secretion of paracrine mediators by nemotic fibroblasts may also 
restrict tumor growth by induction of senescence and differentiation of cancer 
cells, emphasizing the complex role of tumor stroma in the progression and 
restriction of tumor growth [12, 39]. 
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4.11 The summary of results 
 
The results of this thesis indicate that when primary fibroblasts lose their solid 
support, they tend to cluster to a multicellular spheroid in a fibronectin-integrin 
dependent manner. This interaction leads to a rapid induction of stress-related 
autophagy, and sequential withdraw from the cell-cycle to cellular quiescence. 
These events lead to the secretion of tumor-associated cytokines, chemokines, 
growth factors and proteases, which attenuated tumor growth by inducing 
cellular senescence and the differentiation of malignant RT keratinocytes in a 
mouse xenograft models (Figure 12).  
 
 
Figure 12. The schematic summary of major results.  
 - Concluding remarks - 
62 
CONCLUDING REMARKS 
 
Fibroblast activation plays an important role in many physiological and 
pathophysiological conditions, such as wound healing and carcinogenesis. 
Regardless of the considerable impact of fibroblast activation on the progression 
of these conditions, very little is known of the events and mechanisms leading to 
this activation [12]. CAFs, and myofibroblasts, are highly heterogeneous cell 
populations [255]. Hence they probably can be activated by several different 
mechanisms. The present results show that fibroblasts can be activated solely by 
changing their growth environment, and that this activation is mediated by an 
abnormal FN-integrin interaction, indicating that fibroblasts can be activated in 
conditions where their normal growth properties change dramatically. 
Furthermore, both tumors and wound healing, the conditions where activated 
fibroblasts are found, express altered ECM compositions [7, 198].  
Autophagy has a prominent role in the activation of CAFs in response to 
tumor cell stimulus [135]. This is in agreement with our finding showing that 
autophagy has an essential role during nemotic activation. Interestingly, in co-
culture or through conditioned media, tumor cells are known to cause 
spontaneous clustering of fibroblasts, which resembles fibroblast spheroid 
formation [177, 178]. In addition, we showed that malignant keratinocytes were 
able to potentiate nemotic activation. These results suggest that our 
experimental model of fibroblast activation, nemosis, shares many features of 
fibroblasts activation in vivo, although more specific studies are needed to 
reveal the precise mechanism of nemosis and its connection to in vivo 
situations. 
The nemotic phenotype was associated with the upregulation of secreted 
molecules. Interestingly, this phenotype is very similar to that seen in cellular 
senescence. Nemosis shares also other features related to senescence, although 
it lacks some of the hallmarks, indicating that nemosis is a similar, but not 
identical stress response to senescence. Cell cycle arrest, the downregulation of 
the cytoskeleton, and the induction of secretory phenotype suggest that nemotic 
activation is directed to paracrine modulation of other cells in the 
microenvironment (summarized in Figure 13 [175]). 
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Figure 13. The paracrine effects of nemosis-associated secretory 
phenotype to other cell types. Reprinted with permission from ref [175]. 
 
In cell culture experiments, nemotic fibroblasts can either stimulate cancer 
cell proliferation or cause differentiation, which was limited to c-Met negative 
cells [175]. In this study, we show that nemotic fibroblasts promote tumor cell 
senescence in xenograft experiments. This is in agreement with earlier 
publications showing that SASP factors can induce senescence in a cell-
autonomous or cell-non-autonomous manner [173], and that stromal activation 
can lead to tumor cell senescence [256].  
In conclusion, our results indicate that nemosis is a powerful mechanism for 
fibroblast activation and a suitable model for studies on cellular events leading 
to activation and crosstalk between tumor cells and fibroblasts.  
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